Spondyloarthritis & psoriatic arthritis
International Map of Axial Spondyloarthritis (IMAS): results from the perspective of 5557 patients from 27 countries around the globe
Authors' conclusion
IMAS shows the global profile of patients with axSpA, highlighting unmet needs, lengthy delays in diagnosis and high burden of disease in patients with axSpA worldwide.
Study context
- Population
- Unselected patients with axial spondyloarthritis (axSpA) from Europe, Asia, North America, Latin America and Africa, 2017–2022
- Participants
- 5,557 patients
- Outcome
- Global profile and burden of axSpA (patient perspective)
Methodological detailsonline survey (2017-2022), unselected patients, global (Europe, Asia, North America, Latin America and Africa)
- Online survey (2017-2022)
- Unselected patients
- Global (Europe, Asia, North America, Latin America and Africa)
Main finding
As reported in the abstract
- Age, mean ±SD (years)
- 43.9 ±12.8
- Female
- 55.4%
- University education
- 46.2%
- Employed
- 51.0%
- Diagnostic delay, mean ±SD (years)
- 7.4 ±9.0
- Diagnostic delay, median (years)
- 4.0
- Symptom duration, mean ±SD (years)
- 17.1 ±13.3
- Active disease (BASDAI ≥4)
- 75.0%
- Poor mental health (12-item General Health Questionnaire ≥3)
- 59.4%
- Primary care physician visits in prior year
- 4.6
- Rheumatologist visits in prior year
- 3.6
- Ever taken NSAID
- 78.6%
- Ever taken bDMARD
- 48.8%
- Ever taken csDMARD
- 43.6%
- Greatest fear: disease progression
- 55.9%
- Greatest hope: relieve pain
- 54.2%
Observational data: associations, not effects.
Original publication
International Map of Axial Spondyloarthritis (IMAS): results from the perspective of 5557 patients from 27 countries around the globe. RMD Open. Published 8 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →